PepGNP-COVID19
Phase 2Biologic
PepGNP-COVID19 is one of 29 biologic programs targeting COVID-19 Vaccine. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
PepGNP-COVID19
GGylden Pharma Ltd
Phase 2
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Benadryl
PParkedale
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-19 Vaccine1 trial
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07183709·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PepGNP-COVID19. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- GGylden Pharma Ltd